{"entity":{"id":"ahod2131","kind":"trial","name":"AHOD2131 (COG / NCTN)","aka":[],"tldr":"Asks whether early-stage Hodgkin lymphoma in children and adults can be treated with immunotherapy instead of some chemotherapy and radiation.","summary":"AHOD2131, trial NCT05675410 run by the Children's Oncology Group and the NCI, asks whether early-stage classical Hodgkin lymphoma in children and adults aged 5 to 60 can be treated with brentuximab vedotin plus nivolumab in a response-adapted design, instead of some chemotherapy and radiation. It uses PET after two cycles to steer therapy, has progression-free survival as its primary endpoint, measures late effects, and is ongoing with no results yet. Nuclide links it to Hodgkin lymphoma, PET-adapted therapy, brentuximab vedotin, nivolumab, the Children's Oncology Group, Kara M. Kelly, the idea of chemotherapy-free early-stage Hodgkin treatment and the S1826 paper. Whether immunotherapy can spare young patients the late effects of chemotherapy and radiation without losing cures is the question it exists to answer.","status":"recruiting","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT05675410","url":"https://clinicaltrials.gov/study/NCT05675410"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":["pet-adapted-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05675410","phase":"3","setting":"Newly diagnosed stage I-II classical Hodgkin lymphoma, age 5-60: standard therapy vs brentuximab vedotin + nivolumab (response-adapted), with or without radiation","sponsor":"Children's Oncology Group / NCI","enrolledBasis":"registry","outcomes":[]},"route":"/trials/ahod2131/","neighbours":{"technology":[{"id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/"}]}}